Itropide

# Itropide ## Overview - **Classification**: Antimuscarinic, Antispasmodic agent - **Mechanism**: Competitively antagonizes acetylcholine at muscarinic receptors, leading to smooth muscle relaxation in GI and urinary tracts, and decreased glandular secretions. ## Primary Indications 1. **Irritable Bowel Syndrome (IBS)** - Symptomatic relief of cramping, abdominal pain, and spasms. 2. **Overactive Bladder (OAB)** - Treatment of symptoms such as urinary urgency, frequency, and urge incontinence. 3. **Nocturnal Enuresis** - In children, for bladder instability when other measures fail. ## Adult Dosing ### Standard Dosing **Irritable Bowel Syndrome (IBS)** - **Dose**: **20 mg** - **Frequency**: Twice daily (BID) or Three times daily (TID) - **Route**: Oral - **Maximum Dose**: **80 mg/day** **Overactive Bladder (OAB)** - **Dose**: **40 mg** - **Frequency**: Once daily (QD) - **Route**: Oral - **Maximum Dose**: **40 mg/day** (may start at **20 mg QD** and titrate) ### Dose Adjustments - **Renal Impairment**: - CrCl 30-60 mL/min: Reduce dose by 25%. - CrCl <30 mL/min: Reduce dose by 50%. - **Hepatic Impairment**: Use with caution. Consider a 50% dose reduction for severe impairment (Child-Pugh C). - **Elderly Patients**: Start at lower end of dosing range (**10-20 mg/day** for IBS, **20 mg QD** for OAB) due to increased sensitivity to anticholinergic effects. ## Pediatric Dosing ### Neonates (0-28 days) - **Dose**: Not recommended. - **Special Notes**: High risk of serious adverse effects (e.g., paralytic ileus, respiratory depression) due to immature organ systems. ### Infants (1-12 months) - **Dose**: Not typically recommended for routine use. - **Special Notes**: Only under specialist supervision for specific, severe conditions where benefits outweigh risks. ### Children (1-12 years) **Nocturnal Enuresis / Bladder Instability** - **Dose**: **0.4 mg/kg/day** - **Frequency**: Divided into 2-3 doses - **Route**: Oral - **Maximum**: **40 mg/day** - **Special Notes**: Start with lowest effective dose. Monitor for anticholinergic side effects. ### Adolescents (13-18 years) - **Dose**: Initiate with lower adult doses. - **Frequency**: As per adult recommendations. - **Route**: Oral - **Maximum**: Adult maximum dose **(80 mg/day for IBS, 40 mg/day for OAB)**. ## Safety Information ### Contraindications - **Absolute**: Angle-closure glaucoma - **Absolute**: Urinary retention or gastric retention - **Absolute**: Myasthenia gravis - **Absolute**: Severe ulcerative colitis, toxic megacolon - **Relative**: Obstructive uropathy, prostatic hypertrophy ### Common Adverse Effects - **Very Common (>10%)**: Dry mouth, blurred vision, constipation, dizziness - **Common (1-10%)**: Tachycardia, nausea, headache, drowsiness - **Serious but Rare**: Angioedema, severe urinary retention, heat stroke, CNS depression or excitation (especially in elderly). ### Key Drug Interactions - **Other Anticholinergics**: Increased risk of anticholinergic side effects (e.g., tricyclic antidepressants, antihistamines, phenothiazines). - **Cholinesterase Inhibitors**: May antagonize effects of cholinesterase inhibitors (e.g., donepezil, rivastigmine). - **Opioids**: Increased risk of severe constipation and paralytic ileus. ## Monitoring & Follow-up - **Before Treatment**: Assess for conditions like glaucoma, urinary retention. Baseline bowel/bladder function. - **During Treatment**: Monitor for symptom improvement. Assess for anticholinergic side effects (e.g., dry mouth, constipation, urinary difficulty, blurred vision). - **Clinical Signs**: Watch for excessive thirst, reduced urination, vision changes, confusion, especially in elderly. ## Clinical Pearls - 💡 **Tip 1**: Take with food or milk if stomach upset occurs. - 💡 **Tip 2**: To manage dry mouth, recommend sugarless gum/candy or frequent sips of water. - 💡 **Tip 3**: Counsel patients on potential for blurred vision or dizziness; caution driving or operating machinery. - 💡 **Tip 4**: Advise patients to avoid overheating and stay hydrated, as Itropide can impair sweating. > **⚠️ Important**: This information is for educational purposes only. Always consult current prescribing information, local guidelines, and clinical judgment before prescribing.